Clinical Pharmacokinetics of Upadacitinib: Review of Data Relevant to the Rheumatoid Arthritis Indication Mohamed-Eslam F. MohamedBen KlünderAhmed A. Othman Review Article Open access 23 December 2019 Pages: 531 - 544
Pharmacokinetics and Pharmacodynamics of Approved and Investigational P2Y12 Receptor Antagonists Uta SchillingJasper DingemanseMike Ufer Review Article 13 February 2020 Pages: 545 - 566
Clinical Pharmacokinetics and Pharmacodynamics of Imipenem–Cilastatin/Relebactam Combination Therapy Matthew W. McCarthy Review Article 03 February 2020 Pages: 567 - 573
Exposure–Response Relationships for the Efficacy and Safety of Risankizumab in Japanese Subjects with Psoriasis Ahmed A. SuleimanAmit KhatriAhmed A. Othman Original Research Article 31 October 2019 Pages: 575 - 589
A Population Pharmacokinetic Model Does Not Predict the Optimal Starting Dose of Tacrolimus in Pediatric Renal Transplant Recipients in a Prospective Study: Lessons Learned and Model Improvement Louise M. AndrewsBrenda C. M. de WinterKarlien Cransberg Original Research Article Open access 26 October 2019 Pages: 591 - 603
Favorable Pharmacokinetic Characteristics of Extended-Half-Life Recombinant Factor VIII BAY 94-9027 Enable Robust Individual Profiling Using a Population Pharmacokinetic Approach Alexander SolmsAlfonso IorioDirk Garmann Original Research Article Open access 21 November 2019 Pages: 605 - 616
Quantitative Assessment of Elagolix Enzyme-Transporter Interplay and Drug–Drug Interactions Using Physiologically Based Pharmacokinetic Modeling Manoj S. ChineyJuki NgMohamad Shebley Original Research Article Open access 12 November 2019 Pages: 617 - 627
Fetal Physiologically Based Pharmacokinetic Models: Systems Information on Fetal Blood Components and Binding Proteins Khaled AbduljalilMasoud JameiTrevor N. Johnson Original Research Article 07 November 2019 Pages: 629 - 642
Midazolam Pharmacokinetics in Obese and Non-obese Children and Adolescents Christina GadeEva SverrisdóttirHelle Holst Original Research Article 19 November 2019 Pages: 643 - 654
Comment on “Levothyrox® New and Old Formulations: Are They Switchable for Millions of Patients?” Rudolf HoermannJohn E. M. MidgleyJohannes W. Dietrich Letter to the Editor 31 March 2020 Pages: 655 - 657